Antibody formats describe the physical architecture of an antibody molecule, whether it is a full-length immunoglobulin, a fragment, or a recombined multi-specific construct. Knowing these formats matters because therapeutic performance (specificity, half-life, tissue penetration, manufacturability, safety) is tightly linked to structure. From early monoclonal antibodies to today’s sophisticated multispecifics antibodies, each design advances how we diagnose and treat disease. Modified versions of antibodies have been designed to improve certain properties or functionalities, e.g. to enhance their therapeutic or diagnostic potential.
Two identical binding sites each recognize the same target antigen.
Monoclonal antibodies revolutionized medical therapeutics in the 1980s following the development of hybridoma technology. This technology enabled the production of recombinant antibodies that were identical in their antigen recognition, thereby providing a consistent therapeutic tool in various medical applications, notably in oncology and autoimmune diseases.
A heterogeneous assortment of molecules assembled by researchers inspired by the modular nature of antibodies, such as Fab, scFv, and single-domain (VHH) fragments.1
Antibody fragments retain binding affinity while improving tissue penetration and enabling formats such as radio-immunoconjugates and CAR-T recognition domains. These formats also contribute to the development of recombinant antibody formats that allow for greater flexibility in targeting specific disease mechanisms.
Two unique binding sites are directed at two different antigens or two different epitopes on the same antigen.
Bispecific antibodies' dual-targeting feature allows them to perform complex biological tasks such as linking tumor cells to effector cells to enhance cell destruction, a function not achievable with traditional mAbs. This functionality has been leveraged in recent therapeutic approaches, particularly in cancer immunotherapy.2
Bispecific Antibody Expression →
Extend the concept to three or more specificities, allowing simultaneous blockade or activation of multiple pathways in complex diseases such as solid tumors. Emerging trispecific antibodies further build on this model, engaging multiple target antigens and immune cells to boost therapeutic efficiency.
Covalently attach a cytotoxic payload to a targeting antibody, delivering chemotherapy directly to cancer cells while sparing healthy tissue. This targeted delivery is enhanced by innovations in protein engineering and antibody variant development.
Example: trastuzumab-emtansine for HER2-positive breast cancer.
ADC High-throughput Antibody Conjugation →
The structural format of an antibody significantly influences its therapeutic function and clinical performance. Traditional monoclonal antibodies are highly specific but typically bind to only one target antigen, limiting their versatility. Antibody fragments, on the other hand, are smaller and more flexible, allowing for improved tissue penetration and broader applications.
Engineered formats such as multispecific antibodies and antibody-drug conjugates go even further, enabling mechanisms like cell bridging, receptor clustering, and targeted delivery of cytotoxic agents, which are capabilities that conventional formats cannot achieve. Additionally, integrating effector cells through engineered antibody constructs enhances therapeutic action by leveraging the body's immune system to combat disease. Advances in protein engineering and recombinant DNA technology continue to redefine what's possible in antibody development.
Choosing the right antibody format ensures that the therapeutic strategy aligns with the clinical objective, ultimately improving treatment outcomes.
Nelson, A. L. (2010). Antibody fragments: Hope and hype. MAbs, 2(1), 77. https://doi.org/10.4161/mabs.2.1.10786
Kontermann, R. E. (2012). Dual targeting strategies with bispecific antibodies. MAbs, 4(2), 182. https://doi.org/10.4161/mabs.4.2.19000
Antibody discovery and development remain strategic priorities for major pharmac……
VHH antibodies are single-domain antibody fragments derived from the unique heav……
As of the end of 2025, 21 ADCs have been approved globally, with four new approv……
Antibody engineering has progressed beyond classical depletion and neutralizatio……
You can also contact us on the Scientist and Science Exchange marketplaces.
